Quest Diagnostics Inc vs Harley-Davidson Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Harley-Davidson Inc trades at $26.75 (market cap $2.80B). The key difference: Quest Diagnostics Inc is far larger — about 8.9× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Harley-Davidson Inc for 91 Days on average.
| DGX | HOG | |
|---|---|---|
Market Cap | $25.06B | $2.80B |
Volume | 927,361 | 2,093,216 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $28.46 |
52-Week Low | $173.49 | $17.19 |
Typical Hold Time | 56 Days | 91 Days |
Enterprise Value | $30.82B | $3.22B |
Dividend Yield | 1.52% | 2.78% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Harley-Davidson (HOG) trades at $26.75, down 0.71% on the day, with a bullish technical signal and mixed earnings history. The stock shows attractive valuation ratios, including a P/E of 14.97 and P/S of 0.72, but faces declining revenue and net income margins. Recent news highlights tariff exposure and a data breach, while analyst consensus is a 'Hold' with a $28.50 price target. Cash flow trends are volatile, with 2025 showing a net inflow of $1.35 billion driven by investing activities.
The outlook for HOG is cautious due to fundamental pressures, including falling profitability and revenue, offset by low valuations and a dividend. Key risks include competitive threats and sensitivity to tariffs. Upside potential exists if the 'Back to the Bricks' strategy revives growth, but investors should weigh margin erosion against valuation support.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →